Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.65 |
| ▸ | SCN9A | Q15858 | 6/20 | 0.56 |
| ▸ | AVPR1B | P47901 | 3/20 | 0.53 |
| ▸ | ATF4 | P18848 | 1/20 | 0.50 |
| ▸ | HTR7 | P34969 | 1/20 | 0.50 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.47 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.47 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.47 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.47 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.47 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4501875 | 0.85 | HRH3 (0.63) | HRH3AVPR1B | |
| SCHEMBL2208923 | 0.85 | HRH3 (0.55) | HRH3AVPR1BPDE3BPDE3A | |
| SCHEMBL2209038 | 0.84 | HRH3 (0.59) | HRH3SCN9AATF4 | |
| SCHEMBL4490636 | 0.82 | HRH3 (0.64) | HRH3AVPR1B | |
| SCHEMBL2208642 | 0.82 | HRH3 (0.78) | HRH3SCN9A | |
| SCHEMBL1381470 | 0.81 | HRH3 (0.63) | HRH3SCN9AATF4BMPR1BBMPR1A | |
| SCHEMBL1379252 | 0.80 | HRH3 (0.61) | HRH3SCN9AATF4PDE3BPDE3A | |
| SCHEMBL2211794 | 0.80 | HRH3 (0.98) | HRH3SCN9A | |
| SCHEMBL1381691 | 0.79 | HRH3 (0.62) | HRH3SCN9AAVPR1BATF4 | |
| SCHEMBL2210534 | 0.79 | HRH3 (0.60) | HRH3SCN9AATF4PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1805166-B1 | QUINOLINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-07-27 | — | — | EP | claimed |
| JP-4660553-B2 | — | — | 2011-03-30 | — | — | JP | claimed |
| US-7534891-B2 | Quinoline derivatives as H3R inverse agonists | HOFFMAN-LA ROCHE INC. (US) | 2009-05-19 | — | — | US | claimed |
| JP-2008517003-A | — | — | 2008-05-22 | — | — | JP | claimed |
| EP-1805166-A1 | QUINOLINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2007-07-11 | — | — | EP | claimed |
| WO-2006045416-A1 | QUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-04 | — | — | WO | claimed |
| US-20060084679-A1 | Quinoline derivatives as H3R inverse agonists | HOFFMANN-LA ROCHE INC. | 2006-04-20 | — | — | US | claimed |
| EP-1805166-B1 | QUINOLINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-07-27 | — | — | EP | disclosed |
| US-7534891-B2 | Quinoline derivatives as H3R inverse agonists | HOFFMAN-LA ROCHE INC. (US) | 2009-05-19 | — | — | US | disclosed |
| EP-1805166-A1 | QUINOLINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006045416-A1 | QUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-04 | — | — | WO | disclosed |
| US-20060084679-A1 | Quinoline derivatives as H3R inverse agonists | HOFFMANN-LA ROCHE INC. | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084679-A1 | Quinoline derivatives as H3R inverse agonists | HRH3, HRH4, HRH1 | HRH3 1/4885SCN9A 690/4885AVPR1B 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.